Access Pharmaceuticals, Inc. - Product Pipeline Review - 2012

Access Pharmaceuticals, Inc. – Product Pipeline Review – 2012

Summary

Global Market Direct’s pharmaceuticals report, “Access Pharmaceuticals, Inc. - Product Pipeline Review - 2012” provides data on the Access Pharmaceuticals, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Access Pharmaceuticals, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Access Pharmaceuticals, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Access Pharmaceuticals, Inc. - Brief Access Pharmaceuticals, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Access Pharmaceuticals, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Access Pharmaceuticals, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Access Pharmaceuticals, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Access Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Access Pharmaceuticals, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Access Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Access Pharmaceuticals, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Access Pharmaceuticals, Inc. and identify potential opportunities in those areas.

Keywords

Current R&D Portfolio of Access Pharmaceuticals, Inc.; Access Pharmaceuticals, Inc. - Key Therapeutics; Access Pharmaceuticals, Inc. - Pipeline Overview and Promising Molecules; Access Pharmaceuticals, Inc. - News; Access Pharmaceuticals, Inc. - Latest Updates; Access Pharmaceuticals, Inc. - Pipeline; Access Pharmaceuticals, Inc. - Discontinued/Dormant Projects SHOW LESS READ MORE >

2
List of Tables 6
List of Figures 7
Access Pharmaceuticals, Inc. Snapshot 8
Access Pharmaceuticals, Inc. Overview 8
Key Information 8
Key Facts 8
Access Pharmaceuticals, Inc. – Research and Development Overview 9
Key Therapeutic Areas 9
Access Pharmaceuticals, Inc. – Pipeline Review 12
Pipeline Products by Stage of Development 12
Pipeline Products – Monotherapy 13
Pipeline Products – Combination Treatment Modalities 14
Access Pharmaceuticals, Inc. – Pipeline Products Glance 15
Access Pharmaceuticals, Inc. Clinical Stage Pipeline Products 15
Phase II Products/Combination Treatment Modalities 15
Access Pharmaceuticals, Inc. – Early Stage Pipeline Products 16
Pre-Clinical Products/Combination Treatment Modalities 16
Access Pharmaceuticals, Inc. – Drug Profiles 17
Alchemix 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
Angiolix 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
CobOral hGH 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
CobOral Insulin 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Oral Infertility Drugs 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Prodrax 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
ProLindac 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
ProLindac + Paclitaxel 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Sodium Phenylbutyrate 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Thiarabine 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Access Pharmaceuticals, Inc. – Pipeline Analysis 31
Access Pharmaceuticals, Inc. – Pipeline Products by Therapeutic Class 31
Access Pharmaceuticals, Inc. – Pipeline Products By Target 33
Access Pharmaceuticals, Inc. – Pipeline Products by Route of Administration 34
Access Pharmaceuticals, Inc. – Pipeline Products By Mechanism of Action 35
Access Pharmaceuticals, Inc. – Recent Pipeline Updates 36
Access Pharmaceuticals, Inc. - Dormant Projects 37
Access Pharmaceuticals, Inc. – Company Statement 38
Access Pharmaceuticals, Inc. – Locations And Subsidiaries 40
Head Office 40
Other Locations & Subsidiaries 40
Access Pharmaceuticals, Inc., Recent Developments 41
Access Pharmaceuticals, Inc.- Press Release 41
Jun 28, 2012: Access Pharma Announces Positive Data From MuGard Phase IV Clinical Trial In Oral Mucositis At MASCC/ISOO 2012 Symposium 41
Jun 26, 2012: Access Pharma To Report New MuGard Clinical Trial Data At MASCC/ISOO Symposium 42
Apr 17, 2012: Access Pharma Announces Interim Data From MuGard Phase IV Clinical Trial In Oral Mucositis 43
Apr 04, 2012: Access Pharmaceuticals Announces Addition Of MuGard On Formulary At Memorial Sloan-Kettering Cancer Center 44
Feb 24, 2012: Rhei Pharmaceuticals Receives Final Marketing Approval From SFDA Of China For MuGard 44
Dec 03, 2009: Access Pharmaceuticals Launches MuGard For The Treatment Of Oral Mucositis In Europe 45
Aug 03, 2009: Access Pharmaceuticals Provides Update On Prolindac Clinical Development Program 45
Jul 07, 2009: ACCESS's Thiarabine Demonstrates A Reduction Of Both Inflammatory And Erosive Disease Parameters In Rheumatoid Arthritis 46
Jun 07, 2009: Access's Thiarabine Demonstrates A Reduction Of Both Inflammatory And Erosive Disease Parameters In Rheumatoid Arthritis 47
Jun 04, 2009: Access Pharmaceuticals Announces Publication Of Thiarabine Combination Data 47
Jun 02, 2009: Access Pharmaceuticals Provides Update On ProLindac Phase 2 Ovarian Cancer Trial And Clinical Development Plan 48
Apr 20, 2009: SpePharm Announces European Launch Of MuGard 49
Mar 06, 2009: Access Pharmaceuticals Announces Positive ProLindac Phase 2 Ovarian Cancer Clinical Trial Results 50
Feb 26, 2009: Access Pharmaceuticals Closes Acquisition Of Macrochem Corp. 50
Jan 26, 2009: Access Pharmaceuticals Presents The Combination Data On The Angiolix Therapeutic Monoclonal Antibody 51
Financial Deals Landscape 52
Access Pharmaceuticals, Inc., Deals Summary 52
Access Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deal Details 56
Partnerships 56
Access Pharma Enters Into Agreement With Pharma Company 56
Access Pharma Enters Into Co-Development Agreement With BioPharma Company 57
Access Pharma Enters Into Specialty Distribution Agreement With BioScrip 58
Access Pharma Enters Into Co-Development Agreement With A Biotech Company 60
Access Pharma Enters Into An Agreement With Stephen T. Sonis 61
Access Pharma Enters Into Co-Development Agreement With bioRASI For Cobalamin-Based Oral Insulin Product 62
Access Pharma Enters Into Co-Marketing Agreement With iMedicor 64
Somanta Pharma Signs Research Agreement With University of Bradford 65
Access Pharma Enters Into Research Collaboration With Hunter-Fleming 66
Access Pharma Enters Into Research Agreement With A Major Pharma Company 67
Somanta Enters Into Co-Development Agreement With London School Of Pharmacy 68
Access Pharma Enters Into Research Collaboration With Drug Delivery Company 69
Merger 70
Somanta Completes Merger With Hibshman Optical 70
Somanta Merges With Bridge Oncology Products 71
Licensing Agreements 72
Southern Research Institute Enters Into Licensing Agreement With Virium Pharma 72
Access Pharma Enters Into License Agreement With JCOM And Dong-A 73
Access Pharma Enters Into Licensing Agreement With Milestone Biosciences 74
Access Pharma Enters Into Licensing Agreement With Jiangsu Aosaikang Pharma 75
Access Pharma Enters Into Licensing Agreement With RHEI Pharma 77
Access Pharma Enters Into Licensing Agreement With SpePharm 78
BioProgress Enters Into Licensing Agreement With Access Pharma 80
Orient Europharma Enters Into Licensing Agreement With Access Pharma 81
EpiTan Enters Into Licensing Agreement With Access Pharma 82
Somanta Enters Into Licensing Agreement With Advanced Cardiovascular Devices 83
Access Pharma Enters Into Licensing Agreement With Wyeth Consumer Healthcare 84
Equity Offering 85
Access Pharma Files Registration Statement For Public Offering Of Units 85
Access Pharma Completes Private Placement Of Units For $5.4 Million 86
Access Pharma Completes Private Placement Of $7.9 Million 88
Access Pharma Completes Private Placement Of $6.3 Million 90
Access Pharma Issues Series A Cumulative Convertible Preferred Stock For $2.73 Million 92
Access Pharma Completes Private Placement Of $12.25 Million 94
Somanta Pharma Completes Private Placement Of $5.9 Million 96
Access Pharma Completes Private Placement Of $9.7 Million 97
Debt Offering 99
Access Pharma Completes Private Placement Of 7.5% Convertible Notes For $0.5 Million 99
Access Pharma Completes Private Placement Of 7.5% Convertible Notes For $0.5 Million 100
Access Pharma Completes Private Placement Of 7.5% Convertible Notes For $5 Million 101
Access Pharma Completes Private Placement Of Secured Convertible Debentures For $2.63 Million 103
Asset Transactions 105
ULURU Acquires Topical Care Business From Access Pharma 105
Acquisition 108
Access Pharma Acquires MacroChem 108
MacroChem Acquires Virium Pharma 110
Access Pharma Acquires Somanta Pharma 111
Appendix 113
Methodology 113
Coverage 113
Secondary Research 113
Primary Research 113
Expert Panel Validation 113
Contact Us 114
Disclaimer 114

List of Tables
Access Pharmaceuticals, Inc., Key Information 8
Access Pharmaceuticals, Inc., Key Facts 8
Access Pharmaceuticals, Inc. – Pipeline by Indication, 2012 11
Access Pharmaceuticals, Inc. – Pipeline by Stage of Development, 2012 12
Access Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, 2012 13
Access Pharmaceuticals, Inc. – Combination Treatment Modalities in Pipeline, 2012 14
Access Pharmaceuticals, Inc. – Phase II, 2012 15
Access Pharmaceuticals, Inc. – Pre-Clinical, 2012 16
Access Pharmaceuticals, Inc. – Pipeline By Therapeutic Class, 2012 32
Access Pharmaceuticals, Inc. - Pipeline By Target, 2012 33
Access Pharmaceuticals, Inc. – Pipeline By Route of Administration, 2012 34
Access Pharmaceuticals, Inc. – Pipeline Products By Mechanism of Action, 2012 35
Access Pharmaceuticals, Inc. – Recent Pipeline Updates, 2012 36
Access Pharmaceuticals, Inc. - Dormant Developmental Projects,2012 37
Access Pharmaceuticals, Inc., Subsidiaries 40
Access Pharmaceuticals, Inc., Deals Summary 52
Access Pharma Enters Into Agreement With Pharma Company 56
Access Pharma Enters Into Co-Development Agreement With BioPharma Company 57
Access Pharma Enters Into Specialty Distribution Agreement With BioScrip 58
Access Pharma Enters Into Co-Development Agreement With A Biotech Company 60
Access Pharma Enters Into An Agreement With Stephen T. Sonis 61
Access Pharma Enters Into Co-Development Agreement With bioRASI For Cobalamin-Based Oral Insulin Product 62
Access Pharma Enters Into Co-Marketing Agreement With iMedicor 64
Somanta Pharma Signs Research Agreement With University of Bradford 65
Access Pharma Enters Into Research Collaboration With Hunter-Fleming 66
Access Pharma Enters Into Research Agreement With A Major Pharma Company 67
Somanta Enters Into Co-Development Agreement With London School Of Pharmacy 68
Access Pharma Enters Into Research Collaboration With Drug Delivery Company 69
Somanta Completes Merger With Hibshman Optical 70
Somanta Merges With Bridge Oncology Products 71
Southern Research Institute Enters Into Licensing Agreement With Virium Pharma 72
Access Pharma Enters Into License Agreement With JCOM And Dong-A 73
Access Pharma Enters Into Licensing Agreement With Milestone Biosciences 74
Access Pharma Enters Into Licensing Agreement With Jiangsu Aosaikang Pharma 75
Access Pharma Enters Into Licensing Agreement With RHEI Pharma 77
Access Pharma Enters Into Licensing Agreement With SpePharm 78
BioProgress Enters Into Licensing Agreement With Access Pharma 80
Orient Europharma Enters Into Licensing Agreement With Access Pharma 81
EpiTan Enters Into Licensing Agreement With Access Pharma 82
Somanta Enters Into Licensing Agreement With Advanced Cardiovascular Devices 83
Access Pharma Enters Into Licensing Agreement With Wyeth Consumer Healthcare 84
Access Pharma Files Registration Statement For Public Offering Of Units 85
Access Pharma Completes Private Placement Of Units For $5.4 Million 86
Access Pharma Completes Private Placement Of $7.9 Million 88
Access Pharma Completes Private Placement Of $6.3 Million 90
Access Pharma Issues Series A Cumulative Convertible Preferred Stock For $2.73 Million 92
Access Pharma Completes Private Placement Of $12.25 Million 94
Somanta Pharma Completes Private Placement Of $5.9 Million 96
Access Pharma Completes Private Placement Of $9.7 Million 97
Access Pharma Completes Private Placement Of 7.5% Convertible Notes For $0.5 Million 99
Access Pharma Completes Private Placement Of 7.5% Convertible Notes For $0.5 Million 100
Access Pharma Completes Private Placement Of 7.5% Convertible Notes For $5 Million 101
Access Pharma Completes Private Placement Of Secured Convertible Debentures For $2.63 Million 103
ULURU Acquires Topical Care Business From Access Pharma 105
Access Pharma Acquires MacroChem 108
MacroChem Acquires Virium Pharma 110
Access Pharma Acquires Somanta Pharma 111

List of Figures
Access Pharmaceuticals, Inc. – Pipeline by Indication, 2012 10
Access Pharmaceuticals, Inc. – Pipeline by Stage of Development, 2012 12
Access Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, 2012 13
Access Pharmaceuticals, Inc. – Combination Treatment Modalities in Pipeline, 2012 14
Access Pharmaceuticals, Inc. – Pipeline By Therapeutic Class, 2012 31
Access Pharmaceuticals, Inc. - Pipeline By Target, 2012 33
Access Pharmaceuticals, Inc. – Pipeline By Route of Administration, 2012 34
Access Pharmaceuticals, Inc. - Pipeline Products By Mechanism of Action, 2012 35